• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2011 - 2015年美国植入式心脏复律除颤器心脏再同步治疗患者的时间趋势和长期预后:来自国家心血管数据注册库的见解

Temporal trends and long-term outcomes among recipients of cardiac resynchronization therapy with defibrillator in the United States, 2011-2015: Insights from the National Cardiovascular Data Registry.

作者信息

Darden Douglas, Peterson Pamela N, Xin Xin, Munir Muhammad Bilal, Minges Karl E, Goldenberg Ilan, Poole Jeanne E, Feld Gregory K, Birgersdotter-Green Ulrika, Curtis Jeptha P, Hsu Jonathan C

机构信息

Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California, San Diego, La Jolla, California.

Division of Cardiology, Denver Health Medical Center, Denver, Colorado.

出版信息

Heart Rhythm O2. 2022 Apr 2;3(4):405-414. doi: 10.1016/j.hroo.2022.03.004. eCollection 2022 Aug.

DOI:10.1016/j.hroo.2022.03.004
PMID:36097450
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9463686/
Abstract

BACKGROUND

Contemporary data on national trends and outcomes in cardiac resynchronization therapy with defibrillator (CRT-D) recipients following the 2012 updated guidelines has not been studied.

OBJECTIVES

This study assessed the trends in long-term outcomes among CRT-D Medicare-aged recipients implanted in 2011-2015.

METHODS

Patients aged ≥65 years undergoing de novo CRT-D implantation in the National Cardiovascular Data Implantable Cardiac Defibrillator Registry from 2011-2015 with follow-up through 2017 using Medicare data were included and stratified by year of implant. Patient characteristics, in-hospital outcomes, and outcomes up to 2 years following implant were evaluated.

RESULTS

Among 53,174 patients (aged 75.6-6.4 years, 29.7% women) implanted with CRT-D from 2011 to 2015, there was an increase in implantations based on guideline-concordant recommendations (81.0% to 84.7%, < .001). Compared to 2011, in-hospital procedural complications decreased in 2015 (3.9% vs 2.9%; adjusted odds ratio, 0.76, 95% confidence interval, 0.66-0.88,  < .001), driven in part by decreased lead dislodgement (1.4% vs 1.0%). After multivariable adjustment, there was a lower risk of all-cause hospitalization, cardiovascular hospitalization, and mortality at 2-year follow-up in 2015 as compared to 2011, while there were no differences in heart failure hospitalizations at follow-up.

CONCLUSION

Among Medicare beneficiaries receiving CRT-D from 2011 to 2015, there was an increase in implantations based on guideline-concordant recommendations. Furthermore, there has been a reduction in in-hospital complications and long-term outcomes, including cardiovascular hospitalization, all-cause hospitalization, and mortality; however, there has been no difference in the risk of heart failure hospitalization after adjustment.

摘要

背景

2012年更新指南发布后,关于心脏再同步化治疗除颤器(CRT-D)植入患者的全国趋势和治疗结果的当代数据尚未得到研究。

目的

本研究评估了2011 - 2015年植入CRT-D的医疗保险年龄患者的长期治疗结果趋势。

方法

纳入2011 - 2015年在国家心血管数据植入式心脏除颤器登记处接受初次CRT-D植入且使用医疗保险数据随访至2017年的年龄≥65岁的患者,并按植入年份进行分层。评估患者特征、住院期间结局以及植入后长达2年的结局。

结果

在2011年至2015年植入CRT-D的53174例患者(年龄75.6±6.4岁,29.7%为女性)中,基于符合指南的推荐进行的植入手术有所增加(从81.0%增至84.7%,P<0.001)。与2011年相比,2015年住院期间手术并发症有所减少(3.9%对2.9%;调整后的优势比为0.76,95%置信区间为0.66 - 0.88,P<0.001),部分原因是导线脱位减少(1.4%对1.0%)。多变量调整后,与2011年相比,2015年2年随访时全因住院、心血管住院和死亡风险较低,而随访时心力衰竭住院情况无差异。

结论

在2011年至2015年接受CRT-D治疗的医疗保险受益人中,基于符合指南的推荐进行的植入手术有所增加。此外,住院并发症和包括心血管住院、全因住院和死亡在内的长期治疗结果有所改善;然而,调整后心力衰竭住院风险无差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c8/9463686/a71797645720/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c8/9463686/a71797645720/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c8/9463686/a71797645720/gr1.jpg

相似文献

1
Temporal trends and long-term outcomes among recipients of cardiac resynchronization therapy with defibrillator in the United States, 2011-2015: Insights from the National Cardiovascular Data Registry.2011 - 2015年美国植入式心脏复律除颤器心脏再同步治疗患者的时间趋势和长期预后:来自国家心血管数据注册库的见解
Heart Rhythm O2. 2022 Apr 2;3(4):405-414. doi: 10.1016/j.hroo.2022.03.004. eCollection 2022 Aug.
2
Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.在国家心血管数据注册植入式心脏复律除颤器登记处中,需要心室起搏的老年患者使用双腔或心脏再同步治疗除颤器的情况和结果。
JAMA Netw Open. 2021 Jan 4;4(1):e2035470. doi: 10.1001/jamanetworkopen.2020.35470.
3
Use of Cardiac Resynchronization Therapy Among Eligible Patients Receiving an Implantable Cardioverter Defibrillator: Insights From the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.在接受植入式心脏复律除颤器的合格患者中使用心脏再同步治疗:来自国家心血管数据注册植入式心脏复律除颤器登记处的见解。
JAMA Cardiol. 2017 May 1;2(5):561-565. doi: 10.1001/jamacardio.2016.5388.
4
Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.心力衰竭合并心房颤动患者心脏再同步治疗的比较效果:来自国家心血管数据注册中心植入式心律转复除颤器注册研究的结果
Circ Heart Fail. 2016 Jun;9(6). doi: 10.1161/CIRCHEARTFAILURE.115.002324.
5
Temporal trends in patient characteristics and outcomes among Medicare beneficiaries undergoing primary prevention implantable cardioverter-defibrillator placement in the United States, 2006-2010. Results from the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.2006-2010 年美国医疗保险受益人群接受初级预防植入式心脏转复除颤器治疗的患者特征和结局的时间趋势。来自国家心血管数据注册中心的植入式心脏转复除颤器登记处的结果。
Circulation. 2014 Sep 2;130(10):845-53. doi: 10.1161/CIRCULATIONAHA.114.008653. Epub 2014 Aug 5.
6
Cardiac Resynchronization Defibrillator Therapy for Nonspecific Intraventricular Conduction Delay Versus Right Bundle Branch Block.心脏再同步除颤器治疗非特异性室内传导延迟与右束支传导阻滞。
J Am Coll Cardiol. 2019 Jun 25;73(24):3082-3099. doi: 10.1016/j.jacc.2019.04.025.
7
Upgrade from implantable cardioverter-defibrillator vs. de novo implantation of cardiac resynchronization therapy: long-term outcomes.从植入式心脏复律除颤器升级与重新植入心脏再同步治疗:长期结果。
Europace. 2021 Jan 27;23(1):113-122. doi: 10.1093/europace/euaa339.
8
Association of body mass index with cardiac resynchronization therapy intention and left ventricular lead implantation failure: insights from the NCDR implantable cardioverter-defibrillator registry.体重指数与心脏再同步治疗意图和左心室导线植入失败的相关性:来自 NCDR 植入式心脏复律除颤器登记处的见解。
J Interv Card Electrophysiol. 2020 Mar;57(2):279-288. doi: 10.1007/s10840-019-00550-x. Epub 2019 Apr 19.
9
Follow-up of patients with new cardiovascular implantable electronic devices: is adherence to the experts' recommendations associated with improved outcomes?新型心血管植入式电子设备患者的随访:是否遵医嘱与改善预后相关?
Heart Rhythm. 2013 Aug;10(8):1127-33. doi: 10.1016/j.hrthm.2013.06.009. Epub 2013 Jun 14.
10
Comparison of left ventricular lead upgrade vs continued medical care among patients eligible for cardiac resynchronization therapy at the time of defibrillator generator replacement: Predictors of left ventricular lead upgrade and associations with long-term outcomes.在更换除颤器发生器时适合心脏再同步治疗的患者中,比较左心室导线升级与继续医疗护理:左心室导线升级的预测因素及其与长期结局的关系。
Heart Rhythm. 2020 Nov;17(11):1878-1886. doi: 10.1016/j.hrthm.2020.05.032. Epub 2020 Jun 1.

引用本文的文献

1
Association between frailty and adverse outcomes after cardiac resynchronization therapy: a systematic review and meta-analysis.心脏再同步治疗后衰弱与不良结局之间的关联:一项系统评价和荟萃分析。
Eur Geriatr Med. 2025 Feb;16(1):165-177. doi: 10.1007/s41999-024-01112-9. Epub 2024 Dec 4.
2
Landmark Evolutions in Time and Indication for Cardiac Resynchronization Therapy: Results from a Multicenter Retrospective Registry.心脏再同步治疗的时间和适应证方面的里程碑式进展:一项多中心回顾性注册研究的结果
J Clin Med. 2024 Mar 25;13(7):1903. doi: 10.3390/jcm13071903.
3
Improved prognosis after cardiac resynchronization therapy over a decade.

本文引用的文献

1
Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018.2004 年至 2018 年美国心力衰竭、急性心肌梗死和中风住院治疗趋势。
Am Heart J. 2022 Jan;243:103-109. doi: 10.1016/j.ahj.2021.09.009. Epub 2021 Sep 25.
2
Trends in 30- and 90-Day Readmission Rates for Heart Failure.心力衰竭 30 天和 90 天再入院率的趋势。
Circ Heart Fail. 2021 Apr;14(4):e008335. doi: 10.1161/CIRCHEARTFAILURE.121.008335. Epub 2021 Apr 19.
3
Clinical outcomes after implantation of quadripolar compared to bipolar left ventricular leads in patients undergoing cardiac resynchronization therapy: a systematic review and meta-analysis.
十余年心脏再同步化治疗预后改善。
Europace. 2023 Jun 2;25(6). doi: 10.1093/europace/euad141.
心脏再同步治疗患者植入四极与双极左心室导线的临床结局比较:系统评价和荟萃分析。
Europace. 2019 Oct 1;21(10):1543-1549. doi: 10.1093/europace/euz196.
4
Use of Cardiac Resynchronization Therapy Defibrillator in US Hospitals.美国医院中心脏再同步治疗除颤器的使用情况。
JAMA Cardiol. 2019 Aug 1;4(8):804-809. doi: 10.1001/jamacardio.2019.1755.
5
Frequency of in-hospital adverse outcomes and cost utilization associated with cardiac resynchronization therapy defibrillator implantation in the United States.美国心脏再同步治疗除颤器植入术后院内不良结局和费用利用的频率。
J Cardiovasc Electrophysiol. 2018 Oct;29(10):1425-1435. doi: 10.1111/jce.13701. Epub 2018 Sep 6.
6
Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure.医院再入院率降低计划实施与心力衰竭患者再入院和死亡率结局的关联。
JAMA Cardiol. 2018 Jan 1;3(1):44-53. doi: 10.1001/jamacardio.2017.4265.
7
Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).沙库巴曲缬沙坦在射血分数降低的心力衰竭患者中的早期应用:来自“遵循指南-心力衰竭(GWTG-HF)”的见解。
JACC Heart Fail. 2017 Apr;5(4):305-309. doi: 10.1016/j.jchf.2016.12.018.
8
Cardiac Resynchronization Therapy: US Trends and Disparities in Utilization and Outcomes.心脏再同步治疗:美国的使用趋势及利用情况与治疗结果的差异
Circ Arrhythm Electrophysiol. 2016 Mar;9(3):e003108. doi: 10.1161/CIRCEP.115.003108.
9
Hospital readmissions reduction program.医院再入院率降低计划。
Circulation. 2015 May 19;131(20):1796-803. doi: 10.1161/CIRCULATIONAHA.114.010270.
10
Angiotensin-neprilysin inhibition versus enalapril in heart failure.血管紧张素-脑啡肽酶抑制剂与依那普利治疗心力衰竭的比较。
N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.